MediWound Q2 FY26 net loss narrows to USD 7.4 million; revenue drops to USD 3.1 million
Reuters2026/08/13 11:06- MediWound posted Q2 revenue of USD 3.1 million, down 45.85% year over year; operating loss widened to USD 9.5 million.
- Net loss narrowed to USD 7.4 million, or USD 0.57 per share, versus USD 13.3 million, on non-cash financial income.
- RD expense rose to USD 5.9 million from USD 3.5 million, reflecting higher investment in the EscharEx Phase III VALUE trial.
- Cash, cash equivalents and deposits totaled USD 36 million at June 30, down from USD 54 million at year-end 2025.
- Full-year 2026 revenue guidance of USD 24-26 million was reaffirmed, with MSA revenue under Vericel’s BARDA contract expected in H2 2026.
Disclaimer: The content of this article solely reflects the author's opinion and does not represent the platform in any capacity. This article is not intended to serve as a reference for making investment decisions.
You may also like
Goldman Sachs: AI storage chip demand is underestimated, South Korean stock market still has 80% upside potential
Goldman Sachs Asia-Pacific Chief Equity Strategist Timothy Moe maintains a KOSPI target of 12,000 points, implying an almost 80% increase from the current level. He points out that the market is systematically underestimating the sustainability of the AI storage chip profit cycle. Capital expenditures by US tech giants may exceed $1.2 trillion next year, and the chip shortage triggered by data center expansion will further intensify in 2027. The current KOSPI is trading at only 5.3 times expected earnings, about half of its historical average.
Norwegian sovereign wealth fund may cut $80 billion US Treasury holdings; high-rated mortgage securities expected to become new favorites
Norway's sovereign wealth fund, with a scale of $2.3 trillions, has recommended reducing government bond holdings and reallocating funds towards higher-yielding fixed income assets.
Barclays names Takeo Kamai head of high-touch sales trading, Japan
Crypto prices
More
